Mendeleev Commun., 2012, 22, 273–274
cule of azlactone 1. This hypothesis was confirmed by computa-
replacement of cycle oxygen by nitrogen was observed, and
(Z)-3-[4-oxo-2-phenyl-1H-imidazol-5(4H)-ylidene]indolin-2-one
9 was isolated in a moderate yield.
In summary, the ultrasound-assisted Erlenmeyer–Plöchl reac-
tion between hippuric acid and isatin made azlactone available,
which may promote its further studying in the fields of hetero-
cyclic and medicinal chemistry.
tional methods.‡
(Z)-2-Benzamido-2-(2-oxoindolin-3-ylidene)acetic acid 4 and
its esters 5a,b were formed from azlactone 1 via oxazolone
moiety cleavage by heating in acetic acid or alkanols, respectively
(Scheme 1).
The formation of azolopyrimidinones was described for reac-
tion of 4-benzylidene azlactone with aminoazoles.9 However,
only heterocyclic amides of N-benzoyl-2-(2-oxoindolin-3-ylidene)-
2-aminoacetic acid can be formed. In our investigations, reaction
of azlactone 1 with 5-amino-3-methylpyrazole was provided as
an example, amide 6 being obtained in a good yield (similarly to
the case with anilines10).
Online Supplementary Materials
Supplementary data associated with this article can be found
in the online version at doi:10.1016/j.mencom.2012.09.016.
References
Compounds 4, 5a,b and 6 were formed only as Z-isomers
from a mixture E,Z-1.§ Apparently, these Z-isomers were stabilized
by intramolecular hydrogen bond between the carbonyl oxygen
in the oxindole moiety and the benzamide NH group.
3-(2-Oxoindolin-3-ylidene)-3,4-dihydroquinoxalin-2(1H)-one
7 identical to the described previously11 was formed in the reac-
tion of 1,2-diaminobenzene with azlactone 1. In this case, the
benzamide moiety in the molecule 1 was cleaved. Product 7 was
obtained in excellent yield as the Z-isomer only. Similar trans-
formation was proposed earlier for the classical Erlenmeyer
reaction of 4-benzylidene azlactone.12
1 (a)Y. Kim, J. Kim and S. B. Park, Org. Lett., 2009, 11, 17; (b) R. Córdoba,
N. S. Tormo, A. F. Medarde and J. Plumet, Bioorg. Med. Chem., 2007,
15, 5300; (c) V. Sharma and J. J. Tepe, Org. Lett., 2005, 7, 5091;
(d) F. Clerici, M. L. Gelmi and D. Pocar, J. Org. Chem., 1999, 64, 726.
2 E. Erlenmeyer, Liebigs Ann. Chem., 1893, 277, 275.
3 (a) H. E. Carter, in Organic Reactions, ed. R. Adams, John Wiley, New
York, 1947, vol. 3, p. 198; (b) M. Crawford and W. T. Little, J. Chem.
Soc., 1959, 729; (c) J. S. Buck and W. S. Ide, J. Am. Chem. Soc., 1932,
54, 3302.
4 (a) A. M. Tikdari, S. Fozooni and H. Hamidian, Molecules, 2008, 13,
3246; (b) S. Paul, P. Nanda, R. Gupta and A. Loupy, Tetrahedron Lett.,
2004, 45, 425; (c) F. M. Bautista, J. M. Campelo, A. Garcia, D. Luna,
J. M. Marinas andA.A. Romero, J. Chem. Soc., Perkin Trans. 2, 2002, 227.
5 K. L. Vine, L. Matesic, J. M. Locke, M. Ranson and D. Skropeta, Anti-
Cancer Agents Med. Chem., 2009, 9, 397.
6 (a) A. Andreani, M. Granaiola, A. Leoni, A. Locatelli, R. Morigi,
M. Rambaldi, V. Garaliene, W. Welsh, S. Arora, G. Farruggia and
L. Masotti, J. Med. Chem., 2005, 48, 5604; (b) A. Andreani, S. Burnelli,
M. Granaiola, A. Leoni, A. Locatelli, R. Morigi, M. Rambaldi, L. Varoli,
N. Calonghi, C. Cappadone, M. Voltattorni, M. Zini, C. Stefanelli,
L. Masotti and R. H. Shoemaker, J. Med. Chem., 2008, 51, 7508.
7 S. Wang, Y. Zhao, G. Zhang, Y. Li, N. Zhang and P. Gong, Eur. J. Med.
Chem., 2011, 46, 3509.
Treatment of lactone 1 with hydrazine-hydrate gave (Z)-3-hy-
drazonoindolin-2-one 8 as the product of oxazolone ring opening.
When thiosemicarbazide was used as the nucleophile, formal
‡
For the computational data, see Online Supplementary Materials.
A typical procedure of oxazolone ring opening. A solution of 200 mg
§
(0.67 mmol) of compound 1 in 10 ml of acetic acid or corresponding
alcohol was refluxed for 1 h, then the solid product was filtered off.
For 4: yellow needles, 195 mg (92%), mp > 300°C. MS (EI, 70 eV)
m/z: 308 (M+). 1H NMR (400 MHz, DMSO-d6) d: 12.86 (s, 1H), 11.28 (s,
1H), 8.01 (d, 2H, J 7.7 Hz), 7.68 (d, 1H, J 7.7 Hz), 7.61 (t, 2H, J 7.7 Hz),
7.29 (d, 1H, J 7.4 Hz), 7.14 (t, 1H, J 7.4 Hz), 7.08–6.92 (m, 2H), 3.32 (s,
1H, H2O exchange). 13C NMR (100 MHz, DMSO-d6) d: 170.7, 167.4,
162.0, 139.7, 137.1, 134.0, 133.3, 130.2, 129.0, 128.7, 128.4, 121.9, 121.2,
118.8, 110.9. Found (%): C, 66.27; H, 3.90; N, 9.01. Calc. for C17H12N2O4
(%): C, 66.23; H, 3.92; N, 9.09.
8 (a) A. H. Abdel-Rahman, E. M. Keshk, M. A. Hanna and Sh. M. El-Bady,
Bioorg. Med. Chem., 2004, 12, 2483; (b) N. G. Kandile, M. A. Latif and
A. El Sayed, Rev. Roum. Chim., 1991, 36, 245.
9 V. A. Chebanov, S. M. Desenko, S. A. Kuzmenko, V. A. Borovskoy, V. I.
Musatov andYu. V. Sadchikova, Izv. Akad. Nauk, Ser. Khim., 2004, 2730
(Russ. Chem. Bull., Int. Ed., 2004, 53, 2845).
10 S. V. Kolisnyk, V. V. Bolotov, O. O. Altukhov and S. V. Shishkina, Zh.
For 5a: yellow needles, 180 mg (78%), mp 217–218°C. MS (EI, 70 eV)
m/z: 322 (M+). 1H NMR (400 MHz, DMSO-d6) d: 12.70 (s, 1H), 11.21 (s,
1H), 7.96 (d, 2H, J 7.4 Hz), 7.65 (d, 1H, J 7.4 Hz), 7.58 (t, 2H, J 7.4 Hz),
7.25 (d, 1H, J 7.4 Hz), 7.17 (t, 1H, J 7.4 Hz), 7.06–6.91 (m, 2H), 4.01
(s, 3H). 13C NMR (100 MHz, DMSO-d6) d: 172.0, 164.7, 162.8, 139.8,
137.7, 133.8, 133.2, 129.9, 129.1, 128.7, 128.1, 122.3, 121.5, 119.2, 111.7,
52.4. Found (%): C, 67.17; H, 4.39; N, 8.71. Calc. for C18H14N2O4 (%):
C, 67.07; H, 4.38; N, 8.69.
Org. Paratsevtych. Khim., 2011, (2), 53 (in Ukrainian).
11 V. V. Bolotov, S. N. Kovalenko, S. V. Kovaleva and V. I. Stepanenko,
Khim. Geterotsikl. Soedin., 2004, 249 [Chem. Heterocycl. Compd. (Engl.
Transl.), 2004, 40, 211].
12 N. J. P. Subhashini and P. Hanumanthu, Indian J. Chem., Sect. B, 1987,
26, 32.
For characteristics of compounds 5b, 6–9, see Online Supplementary
Materials.
Received: 28th February 2012; Com. 12/3882
– 274 –